Q3 FY2026 · ended Sep 30, 2026 · Revenue $0, -100.0% YoY · Filed Nov 6, 2026
CervoMed Inc. (CRVO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $0 and a net loss of $5.9 million.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-5.90M
+23.7% vs year-ago quarter
Operating cash flow
$-5.07M
+21.5% vs year-ago quarter
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
15.13M
+63.5% vs year-ago quarter
Net cash
—
Operating margin
-334924.9%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CRVO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1053691
- Former names
- Diffusion Pharmaceuticals Inc. (until Aug 14, 2023); RestorGenex Corp (until Jan 14, 2016); Stratus Media Group, Inc (until Mar 7, 2014); FERIS INTERNATIONAL, INC. (until Jul 16, 2008); TITAN MOTORCYCLE CO OF AMERICA INC (until Feb 22, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $8,726 | $322,569 |
| Operating income | -$6.1M | -$6.7M | -$8.1M | -$8.3M | -$8.0M |
| Net income | -$5.9M | -$6.6M | -$8.0M | -$8.1M | -$7.7M |
| Operating cash flow | -$5.1M | -$6.9M | -$8.0M | -$6.6M | -$6.5M |
| Total assets | $21.3M | $26.0M | $15.1M | $22.9M | $30.6M |
| Total liabilities | $4.0M | $3.0M | $4.5M | $4.7M | $4.6M |
| Stockholders' equity | $17.4M | $23.0M | $10.6M | $18.2M | $26.0M |
| Cash and investments | $19.6M | $24.9M | $12.9M | $20.9M | $27.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 6, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 13, 2026 | Oct 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 9, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 28, 2026 | Sep 28, 2026 |
All 1001 CervoMed Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.